An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
In recognition of American Heart Month, the American College of Cardiology today released CardioSmart "Survival Guides" for five of the most common heart problems: coronary artery disease, heart failure, arrhythmia, hypertension and heart attack.
The newly approved drug dabigatran is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation, according to updated guidelines from the American College of Cardiology, American Heart Association and the Heart Rhythm Society.
Atrial Fibrillation is the most common cardiac arrhythmia. Its name comes from the fibrillating of the heart muscles of the atria, instead of a coordinated contraction. The result is an irregular heartbeat, which may occur in episodes lasting from minutes to weeks, or it could occur all the time for years. Atrial fibrillation alone is not in itself generally life-threatening, but it may result in palpitations, fainting, chest pain, or congestive heart failure.
A new study published in the journal Pediatrics on Monday examined the risks of consumption of high-caffeine energy drinks on children and young adults. The study notes that these drinks are linked to an array of serious events like heart palpitations, high blood pressure and even cardiac arrest and death. The risk rises if young adults consuming the drink suffer from chronic diseases or take other medications.
Using skin cells from young patients who have a severe genetic heart defect, Stanford University School of Medicine scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells - cardiomyocytes - allowed the researchers for the first time to examine and characterize the disorder at the cellular level.
Researchers from the Hospital Virgen de las Nieves of the University of Granada have identified the most frequent mutations in the gene KCNH2 in patients with long QT syndrome.
Researchers at the University of Utah's Comprehensive Arrhythmia and Research Management Center have found that delayed-enhancement magnetic resonance imaging holds promise for predicting the risks of strokes, the third leading cause of death in the U.S.
Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.
Thousand of people who suffer from irregular heartbeats or conditions termed as arrhythmias are unaware they are at high risk of suffering a stroke. A new survey found that two of three people do not know the warning signs of shortness of breath and palpitations. Experts estimate that more than 4,000 strokes a year could be prevented by better awareness among the general public and doctors of the heart condition atrial fibrillation (AF) this manifests as palpitations and irregular heart beat.
Australian researchers have come one step closer to understanding how the rhythm of the heartbeat is controlled and why many common drugs, including some antibiotics, antihistamines and anti-psychotics, can cause a potentially fatal abnormal heart rhythm.
Boston Scientific Corporation today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI clinical trial. BLOCk-CTI is a prospective, randomized trial evaluating the safety and effectiveness of the Blazer Open-Irrigated Catheter in patients with sustained or recurrent Type 1 atrial flutter.
Scientists in the Hotchkiss Brain Institute at the Faculty of Medicine, University of Calgary, have discovered a new mechanism that nerve cells (neurons) use to fine-tune their electrical output. The exciting discovery, published this week in the prestigious journal Nature Neuroscience, provides new insights about how the activity of the nervous system is regulated at the cellular level.
Cardiac arrests that can be treated by electric stimulation, also known as shockable arrests, were found at a higher frequency in public settings than in the home, according to a National Institutes of Health-funded study appearing in the Jan. 27 issue of the New England Journal of Medicine.
CardioFocus announced that two "live cases" using its Endoscopic Ablation System were recently conducted. The first live case was a satellite transmission performed at Centro Cardiologico Monzino in Milan, Italy; broadcast to the 16th Annual Boston Symposium on Atrial Fibrillation in Boston, MA.
Revolution Analytics, the leading provider of commercial software and support for the popular open source R statistics language, today announced the successful implementation of its signature product, Revolution R Enterprise, by biostatisticians at CardioDX, a genomic research firm.
Skin cells from a patient with an inherited heart disease were the seeds of a stem cell experiment that could help researchers test specific treatments for the disease, known as long QT syndrome. The research results appear in the January 16 issue of the journal Nature.
The abnormal heart rhythm, atrial fibrillation, is increasingly common in patients on dialysis and is linked to a sharp rise in death, in an already at-risk population, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.
Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.
Mayo Clinic is the first in the U.S. to use the first minimally invasive freezing balloon technology for the treatment of atrial fibrillation approved in December by the U.S. Food and Drug Administration. The first patient received the treatment Tuesday, Jan. 4.
Stereotaxis, Inc. announced today that the Company and its existing strategic catheter partner have extended their exclusive worldwide agreement for the distribution of existing approved magnetic ablation catheters through the end of 2015.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.